ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split

Rhea-AI Summary

ENvue Medical (NASDAQ: FEED) has approved a 1-for-12 reverse stock split of its issued and outstanding common stock, expected to become effective on September 1, 2026. FEED will continue trading on the Nasdaq Capital Market under the same ticker, but with new CUSIP 63008J876.

According to ENvue Medical, every twelve pre-split shares will be combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718, while authorized common shares remain at 40,000,000. Fractional shares will be rounded up to the nearest whole share per stockholder, and equity awards and convertible securities will be proportionally adjusted.

News Explained

The 1-for-12 reverse stock split is not expected to change existing holders’ percentage ownership or voting power, apart from minimal fractional-share effects; outstanding options, convertibles, restricted shares, units and warrants will be adjusted proportionally.

Market reaction after 1-for-12 reverse stock split: FEED -10.33%

-10.33% $0.33 31.9x vol

15m delay

-10.33% Vs previous close

-8.5% Trough in 0 min

$0.33 Last Price

$0.30 $0.39 Day Range

$3.66M Market Cap

31.9x Rel. Volume

Following this news, FEED has declined 10.33%, reflecting a significant negative market reaction. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.33. Trading volume is exceptionally heavy at 31.9x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The stock is up +6.0% following this news. An 8.84% reaction followed ENvue’s August 12 equity-finan...

Analysis

The stock is up +6.0% following this news. An 8.84% reaction followed ENvue’s August 12 equity-financing announcement in the historical record. That comparison frames a possible positive response as financing-sensitive, while the active S-3 shelf remains not effective and dilution risk remains relevant.

Key Figures

Reverse split ratio: 1-for-12 Effective date: September 1, 2026 Pre-split shares outstanding: 11,084,616 shares +3 more

6 metrics

Reverse split ratio 1-for-12 Effective September 1, 2026

Effective date September 1, 2026 Post-split trading begins at market open

Pre-split shares outstanding 11,084,616 shares Before the reverse stock split

Post-split shares outstanding 923,718 shares After the 1-for-12 reverse stock split

Authorized common shares 40,000,000 shares Unchanged by the reverse stock split

Common stock par value $0.001 per share Unchanged by the reverse stock split

Historical Context

5 past events · Latest: Aug 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 18	Distribution agreement	Positive	-7.3%	Exclusive UroShield distribution agreement included approximately $2.6 million minimum purchase commitments.
Aug 12	Equity financing facility	Positive	+8.8%	Equity financing facility provided access to up to $50 million in capital.
Aug 04	Manufacturing relocation	Positive	+7.7%	U.S. manufacturing relocation was presented as an operational efficiency and cost-reduction measure.
Jul 23	Platform deployment	Positive	+3.3%	Additional ENvue Navigation Platform deployment expanded use at an existing medical center.
Jul 15	Board appointments	Positive	-8.3%	New directors added clinical, AI governance, and capital markets expertise.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed: three aligned with positive announcements, while two diverged despite positive news.

Key Terms

reverse stock split, cusip number, restricted stock units, exchange agent

4 terms

reverse stock split financial

"today announced that a reverse stock split of the Company’s issued"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

cusip number technical

"but will trade under a new CUSIP number, 63008J876"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

restricted stock units financial

"restricted stock units and warrants of the Company outstanding"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exchange agent financial

"VStock Transfer, LLC, will act as the exchange agent"

An exchange agent is a third party appointed to handle the practical steps when securities are being swapped, such as during mergers, tender offers, or restructurings. Think of it as a trusted post office that collects old shares, verifies ownership, completes required paperwork and regulatory filings, and delivers the new shares or cash to investors; its efficiency and accuracy affect how quickly and safely investors receive the value they're owed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TYLER, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-12 is expected to become effective on September 1, 2026. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on September 1, 2026, under the Company's existing trading symbol "FEED", but will trade under a new CUSIP number, 63008J876.

After giving effect to the reverse stock split of the Company’s Common Stock, each twelve (12) shares of Common Stock will be combined into one (1) share of Common Stock, such that the Company’s 11,084,616 Common Stock outstanding will be reduced to approximately 923,718 shares of Common Stock outstanding (the “Reverse Stock Split”). The Reverse Stock Split has no impact on the Company’s authorized shares, which remains 40,000,000 shares of Common Stock. No fractional shares will be issued as a result of the Reverse Stock Split as any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per stockholder basis.

The Reverse Stock Split was approved by the Company’s board of directors under authority granted by the Company's stockholders at the Company’s Special Meeting of Stockholders held on August 14, 2026.

The Reverse Stock Split will not impact any stockholder's percentage ownership of the Company or voting power, except for minimal effects resulting from the treatment of fractional shares.

All options, convertible securities including preferred stock, restricted stock (vested and unvested), restricted stock units and warrants of the Company outstanding prior to the Reverse Stock Split will be appropriately adjusted.

The Reverse Stock Split will not change the number of authorized shares of preferred stock, or the par value of the Common Stock or preferred stock. After the Reverse Stock Split, the shares of the Company’s Common Stock will have the same proportional voting rights and rights to dividends and distributions. VStock Transfer, LLC, will act as the exchange agent for the Reverse Stock Split. Please contact VStock Transfer, LLC for further information at (212) 828-8436.

About ENvue Medical, Inc.

ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv Israel, the Company focuses on two distinct technology platforms:

• ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
• Acoustic-based therapeutic technologies, including PainShield® and UroShield®, with research and development in Tel Aviv, Israel, and manufacturing operations in the United States, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
  
  

ENvue Medical is committed to advance standards in non-invasive therapy and minimally invasive navigation, with a focus on patient safety, clinical usability, and technology innovation across a range of healthcare environments.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the implementation of the Reverse Stock Split. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com 

Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com

FAQ

What is the reverse stock split ratio for ENvue Medical (NASDAQ: FEED) in 2026?

ENvue Medical is implementing a 1-for-12 reverse stock split, where every twelve shares become one. According to ENvue Medical, this affects issued and outstanding common stock but does not change authorized share counts, voting rights, or proportional ownership, aside from minor rounding for fractional shares.

When will ENvue Medical's (FEED) 1-for-12 reverse stock split take effect?

The reverse stock split is expected to become effective on September 1, 2026. According to ENvue Medical, FEED will begin trading on a post-split basis at the market open that day on the Nasdaq Capital Market, under its existing symbol but a new CUSIP number.

How many ENvue Medical (FEED) shares will be outstanding after the 2026 reverse stock split?

After the 1-for-12 reverse stock split, ENvue Medical expects approximately 923,718 shares outstanding. According to ENvue Medical, this reflects a reduction from 11,084,616 pre-split shares, with each block of twelve existing shares combined into one new share of common stock.

How will fractional shares be handled in ENvue Medical's (FEED) 1-for-12 reverse stock split?

No fractional shares will be issued; they will be rounded up to the nearest whole share per holder. According to ENvue Medical, this rounding approach ensures each stockholder ends up with whole post-split shares, slightly adjusting holdings where fractions would otherwise occur.

Will ENvue Medical's (FEED) reverse stock split change shareholder ownership percentages?

Shareholder ownership percentages are not expected to change materially from the reverse split. According to ENvue Medical, the 1-for-12 combination keeps proportional ownership and voting power the same, except for minimal impacts from rounding up fractional shares to whole shares.

Does the ENvue Medical (FEED) 2026 reverse stock split affect authorized share counts or par value?

The reverse stock split does not affect authorized share counts or par value. According to ENvue Medical, authorized common shares remain at 40,000,000, and the par value of both common and preferred stock stays unchanged after the 1-for-12 split.